<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085163</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40023</org_study_id>
    <secondary_id>EORTC-40023</secondary_id>
    <secondary_id>PETACC-5</secondary_id>
    <nct_id>NCT00085163</nct_id>
  </id_info>
  <brief_title>Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon</brief_title>
  <official_title>Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Study of Adjuvant Therapy With Celecoxib in Combination With Chemotherapy in Patients With Curatively Resected Stage III Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Colorectal Cancer Group (DCCG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EFCR - Egyptian foundation for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EORTC GI Group (EORTC 40023)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GCCD-APIO - Grupo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncológica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GOCCI - Gruppo Oncologico Chirurgico Cooperativo Italiano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GOIRC - Gruppo Oncologico Italiano di Ricerca Clinica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SG - Scandinavian Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TTD - Grupo Español para el Tratamiento de Tumores Digestivos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different
      ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the
      growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known
      whether fluorouracil and leucovorin are more effective with or without celecoxib in treating
      resected stage III adenocarcinoma (cancer) of the colon.

      PURPOSE: This randomized phase III trial is studying celecoxib, fluorouracil, and leucovorin
      to see how well they work compared to fluorouracil and leucovorin in treating patients who
      have undergone surgery for stage III colon cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare disease-free survival of patients with curatively resected stage III
           adenocarcinoma of the colon treated with adjuvant fluorouracil and leucovorin calcium
           with or without celecoxib.

      Secondary

        -  Compare the overall survival, the occurrence of new primary colon cancer, and the
           development of new polyps in patients treated with these regimens.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to ≥ 4 tumor-positive lymph nodes (yes vs no), form of adjuvant
      chemotherapy (infusional vs bolus), low-dose aspirin for cardiovascular prophylaxis (yes vs
      no), and participating center. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive fluorouracil and leucovorin calcium IV for up to 6 courses in
           the absence of disease recurrence or unacceptable toxicity. Patients also receive oral
           celecoxib twice daily.

        -  Arm II: Patients receive oral placebo twice daily and fluorouracil and leucovorin
           calcium as in arm I.

      In both arms, treatment with celecoxib or placebo continues for 3 years in the absence of
      disease recurrence or unacceptable toxicity.

      Patients are followed annually for 2 years.

      PROJECTED ACCRUAL: A total of 1,450 patients (725 per treatment arm) will be accrued for this
      study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time occurrence of new primary colon cancer and new polyps as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTC AE version 2.0 every 3 months in year 1, every 6 months in years 2-3, and annually thereafter</measure>
  </secondary_outcome>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the colon

               -  15 cm above anal verge

               -  Stage III disease (any pT, N1-2, M0)

          -  No rectal cancer

          -  Must have undergone curative radical resection (R0 resection) within the past 6 weeks

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  AST ≤ 5 times upper limit of normal (ULN)

          -  Bilirubin ≤ 1.5 times ULN

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Cardiovascular

          -  None of the following conditions within the past 6 months:

               -  Myocardial infarction

               -  Unstable angina

               -  Symptomatic congestive heart failure

               -  Serious uncontrolled cardiac arrhythmia

               -  Cerebrovascular accident or transient ischemic attack

               -  Deep vein thrombosis

               -  Other significant thromboembolic event

        Pulmonary

          -  No pulmonary embolism within the past 6 months

        Gastrointestinal

          -  No active gastric or duodenal ulceration within the past year

          -  No gastrointestinal bleeding within the past year

          -  No partial or complete bowel obstruction

          -  No known chronic malabsorption

          -  No active inflammatory bowel disease or chronic diarrhea (more than 4 stools/day)

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No AIDS-related illness

          -  No prior hypersensitivity to fluorouracil, leucovorin calcium, celecoxib, other COX-2
             inhibitors, NSAIDs, salicylates, or sulfonamides

          -  No other severe acute or chronic medical condition or laboratory abnormality that
             would preclude study participation, study drug administration, or study results
             interpretation

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance

          -  No concurrent active infection

          -  No other malignancy within the past 5 years except adequately treated carcinoma in
             situ of the cervix or basal cell or squamous cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent sargramostim (GM-CSF) or molgramostim

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  No more than 4 weeks of concurrent orally/nasally inhaled steroids over a 6-month
             period

               -  Concurrent mometasone (or fluticasone) allowed if patients require ≥ 4 weeks of
                  inhaled steroid therapy

          -  At least 30 days since other prior steroids

          -  No concurrent hormonal therapy

        Radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  See Disease Characteristics

          -  No prior total colectomy or other major surgery that would result in substantial
             alteration in transit to absorption of oral medication

        Other

          -  More than 30 days since prior investigational medication

          -  No prior systemic anticancer treatment for colon cancer

          -  No concurrent prophylactic fluconazole

          -  No concurrent lithium

          -  No concurrent chronic* use of full dose aspirin, nonsteroidal anti-inflammatory drugs
             (NSAIDs), or cyclo-oxygenase-2 (COX-2) inhibitors

               -  Aspirin at cardioprotective doses (i.e., 80 mg daily or equivalent) allowed

          -  No concurrent participation in any other clinical study

          -  No other concurrent experimental agents (e.g., other COX-2 inhibitors, matrix
             metalloproteinase inhibitors, inhibitors of the vascular endothelial growth
             factor/Flk-1 pathway, or inhibitors of the epidermal growth factor receptor pathway)
             NOTE: *Chronic use is defined as a frequency of 7 consecutive days (1 week) for more
             than 3 weeks/year or more than 21 days throughout the year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelis J.H. van de Velde, MD, PhD, FRCS, FRCPS</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk J. Richel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Ducreux, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karl-Franzens-University Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck Universitaetsklinik</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Linz Donau</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenanstalten - Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Ziekenhuis</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>'s-Gravenhage</city>
        <zip>2501 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen - Lokatie Lukas</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Lievensberg</name>
      <address>
        <city>Bergen-op-Zoom</city>
        <zip>4624 VT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuisen</name>
      <address>
        <city>Deventer</city>
        <zip>7415 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis St Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <zip>3840 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nijmegen Cancer Center at Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterlandziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <zip>1440 AG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>NL-3083</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schieland Ziekenhuis</name>
      <address>
        <city>Schiedam</city>
        <zip>NL-3116</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis de Honte</name>
      <address>
        <city>Terneuzen</city>
        <zip>NL-4535</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Streekziekenhuis Koningin Beatrix</name>
      <address>
        <city>Winterswyk</city>
        <zip>7101 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken - locatie Weezenlanden</name>
      <address>
        <city>Zwolle</city>
        <zip>NL-8000 GM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>stage III colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

